CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL
Recruiting · NCT06179524 · Registry updated 2025-01-13Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Phase 2 | 2025-01-13 | NCT06179524 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Yongtai Ruike Biotechnology Company Ltd | 2 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hematology Hospital of the Chinese Academy of Medical Sciences | Tianjin | China | 2 |